SGN-CD33A
Monoclonal antibody | |
---|---|
Source | Humanized (from mouse) |
Target | CD33 |
Clinical data | |
Identifiers | |
None | |
Chemical data |
SGN-CD33A is an antibody-drug conjugate (ADC) directed to CD33 designed for the treatment of Acute myeloid leukemia. It consists of a humanized anti-CD33 mAb with 2 engineered cysteine residues. The drug payloads are pyrrolobenzodiazepine (PBD) dimers which are conjugated with a maleimidocaproyl valine-alanine dipeptide linker. PBD dimers exert their biological activity by covalent binding and interstrand cross-linking of DNA.[1]
The drug is currently in phase I clinical trials for Acute myeloid leukemia [2]